Patrick Yassini, MD
Family Medicine · Coronado, CANPI 1649353095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Lumenis BE Inc at 50.3% of the total. Reporting peaked in 2022 at $198 and has fallen 88.4% since, to $23 in 2024. That places this record below the midpoint for family medicine clinicians in CA, where the typical reported total is $232.
Across 8 payments — averaging $35.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$142
- Biohaven Pharmaceutical Holding Company Ltd.$31
- Linus Health, Inc.$25
- Merz North America, Inc.$23
- Novo Nordisk$23
- Clarus Therapeutics Inc.$21
- plus $17 from 1 others
Across 1,699 payments — averaging $1745.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$1.2M
- Valneva Austria GmbH$401K
- Seqirus USA Inc$353K
- Pfizer$323K
- Modernatx, Inc.$288K
- Emergent Biosolutions Inc.$250K
- plus $167K from 5 others
What the payments were for
- Food & beverage$282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Linus Health, Inc. | 1 | $25 |
| Merz North America, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$142
How this compares
$282 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol ErCarvedilol Phosphate | 11 | $1,565 |
| Testosterone Cypionate | 17 | $752 |
| Levothyroxine Sodium | 36 | $519 |
| ProgesteroneProgesterone, Micronized | 15 | $379 |
| Methadone Hcl | 13 | $280 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $222 |
| Rosuvastatin Calcium | 15 | $165 |
| Tramadol Hcl | 11 | $141 |
| Trazodone Hcl | 13 | $86 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Coronado
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.